No dose adjustments required in the elderly, patients with mild renal impairment (estimated CrCl >50 to ≤80 mL/min) and those with hepatic impairment^1,2

Table 1 footnotes:
§ The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
║There is very limited experience with the use of ZAVICEFTA for more than 14 days.
* The dose of ZAVICEFTA in patients with estimated CrCL ≤50 mL/min should be adjusted according to                 recommended doses. CrCL estimated using the Cockcroft-Gault formula.
† To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be                contributing to the infectious process.
‡ To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are       known or suspected to be contributing to the infectious process.

• The elderly
• Patients with mild renal impairment (estimated CrCL from >50 to ≤80 mL/min)
• Patients with hepatic impairment

Table 2 footnotes:
* CrCL estimated using the Cockcroft-Gault formula.
† Dose recommendations are based on pharmacokinetic modelling.
‡ Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on                    haemodialysis days should occur after completion of haemodialysis.
§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only.

When treating for cIAI, cUTI, HAP/VAP or LTO, to be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. 
When treating for cIAI or LTO, to be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

Table 3 footnotes:
*  CrCL estimated using the Schwartz bedside formula.
¶ The total treatment duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
ǁ There is very limited experience with the use of ZAVICEFTA for more than 14 days.
**There is limited experience with the use of ZAVICEFTA in paediatric patients 3 months to < 6 month.

Table 4 footnotes:
*CrCL estimated using the Schwartz bedside formula
† Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
**Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis

Table 5 footnotes:
*CrCL estimated using the Schwartz bedside formula
†Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only

There is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73m²